These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

533 related items for PubMed ID: 26659069

  • 1. Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV.
    Klassen KM, Kimlin MG, Fairley CK, Emery S, Anderson PH, Ebeling PR, STEAL Study Group.
    Osteoporos Int; 2016 May; 27(5):1737-45. PubMed ID: 26659069
    [Abstract] [Full Text] [Related]

  • 2. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
    McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, Myers L, Melbourne K, Ha B, Sax PE.
    J Infect Dis; 2011 Jun 15; 203(12):1791-801. PubMed ID: 21606537
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.
    Cotter AG, Vrouenraets SM, Brady JJ, Wit FW, Fux CA, Furrer H, Brinkman K, Sabin CA, Reiss P, Mallon PW, PREPARE (Preventing Progression of Adipose Tissue Redistribution) Investigators.
    J Clin Endocrinol Metab; 2013 Apr 15; 98(4):1659-66. PubMed ID: 23436922
    [Abstract] [Full Text] [Related]

  • 6. Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial.
    Curran A, Martinez E, Podzamczer D, Lonca M, Barragan P, Crespo M, Falco V, Vidal-Sicart S, Imaz A, Martinez M, Gatell JM, Ribera E.
    Antivir Ther; 2012 Apr 15; 17(4):711-8. PubMed ID: 22374987
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.
    Rasmussen TA, Jensen D, Tolstrup M, Nielsen US, Erlandsen EJ, Birn H, Østergaard L, Langdahl BL, Laursen AL.
    PLoS One; 2012 Apr 15; 7(3):e32445. PubMed ID: 22479327
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.
    Havens PL, Long D, Schuster GU, Gordon CM, Price G, Wilson CM, Kapogiannis BG, Mulligan K, Stephensen CB, Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 117 and 109 study teams.
    Antivir Ther; 2018 Apr 15; 23(7):623-628. PubMed ID: 30260797
    [Abstract] [Full Text] [Related]

  • 15. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
    Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, Gonzales P, Ramirez-Cardich ME, Namwongprom S, Chodacki P, de Mendonca LM, Wang F, Lama JR, Chariyalertsak S, Guanira JV, Buchbinder S, Bekker LG, Schechter M, Veloso VG, Grant RM, Preexposure Prophylaxis Initiative Study Team.
    Clin Infect Dis; 2015 Aug 15; 61(4):572-80. PubMed ID: 25908682
    [Abstract] [Full Text] [Related]

  • 16. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
    Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas JR, Domingo P, Granier C, Pearce H, Sedani S, Gartland M, ASSERT Team.
    Antivir Ther; 2013 Aug 15; 18(7):905-13. PubMed ID: 23899468
    [Abstract] [Full Text] [Related]

  • 17. Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine.
    Haskelberg H, Pocock N, Amin J, Ebeling PR, Emery S, Carr A, STEAL study investigators, Allworth A.
    PLoS One; 2014 Aug 15; 9(4):e94858. PubMed ID: 24722774
    [Abstract] [Full Text] [Related]

  • 18. Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial.
    Boontanondha P, Nimitphong H, Musikarat S, Ragkho A, Kiertiburanakul S.
    Curr HIV Res; 2020 Aug 15; 18(1):52-62. PubMed ID: 31906840
    [Abstract] [Full Text] [Related]

  • 19. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
    Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, Yang O, Dubé MP, Murphy RL, Stein JH, McComsey GA.
    J Infect Dis; 2015 Oct 15; 212(8):1241-9. PubMed ID: 25948863
    [Abstract] [Full Text] [Related]

  • 20. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R, Calza L.
    AIDS Patient Care STDS; 2008 Apr 15; 22(4):279-90. PubMed ID: 18290748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.